Development of siRNA delivery system tot tumor vesssels: optimization of intracellular trafficking and pharmacokinetics

2014 Fiscal Year Final Research Report

• Project/Area Number: 25893001
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Medical pharmacy
• Research Institution: Hokkaido University
• Principal Investigator: SAKURAI Yu 北海道大学, 薬学研究科(研究院), その他 (00707234)
• Project Period (FY): 2013-08-30 – 2015-03-31
• Keywords: siRNA / リポソーム / アクティブターゲティング / 血管新生阻害療法 / がん治療

Outline of Final Research Achievements

Angiogenesis is indispensable for a progression of cancer via a supplement with oxygen and nutrients. I developed a nanocarrier for delivering small interfering RNA (siRNA) to tumor endothelial cells (TECs). I called the carrier “RGD-MEND”. SiRNA is encapsulated in lipid envelope of RGD-MEND, and further cyclic RGD, which recognize TECs, is displayed on the surface of RGD-MEND. When the formulated siRNA to inhibit a growth of TECs was administered into tumor bearing-mice via the tail vein, tumor growth was significantly inhibited. In addition, mRNA expression level or the target gene was reduced by siRNA injection.

Free Research Field

薬物送達学